SunstarTV Bureau: On early Monday as the Drug Controller General of India (DGCI) has approved the Russia’s Sputnik V vaccine for emergency use, along with this, India has three vaccines to combat against Covid-19 including Covishield-the Oxford-Astrazeneca vaccine manufactured by the Serum Institute of India- and Bharat Biotech’s Covaxin.
Meanwhile, the Russian Direct Investment Fund (RDIF) has issued a release where it added India is the most populated country to register the Russian vaccine.
According to RDIF released report, the vaccine has been registered in India under the emergency use authorization procedure based on results of clinical trials in Russia as well as positive data of additional Phase 3 local clinical trials in India conducted in Partnership with Dr. Reddy’s Laboratories.
Moreover, RDIF has agreements with India’s leading pharmaceutical companies as Gland Pharma, HeteroBiopharma, Panacea Biotech, Stelis Biopharma, and Virchow Biotech which brought an aim to produce more than 850 million doses per year.
